Education
About Us
Working with TipRanks
Follow Us
Verastem (VSTM)
NASDAQ:VSTM
VSTM Stock Chart & Stats
$7.93
-$0.30(-4.59%)
At close: 4:00 PM EST
$7.93
-$0.30(-4.59%)
Day’s Range― - ―
52-Week Range$3.46 - $11.25
Previous CloseN/A
Volume547.29K
Average Volume (3M)2.41M
Market Cap
$544.89M
Enterprise Value$597.75M
Total Cash (Recent Filing)$137.71M
Total Debt (Recent Filing)$78.92M
Price to Earnings (P/E)―
Beta0.91
Next Earnings
Mar 12, 2026EPS Estimate
-0.55Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.35
Shares Outstanding66,776,010
10 Day Avg. Volume3,115,275
30 Day Avg. Volume2,412,378
Financial Highlights & Ratios
PEG Ratio0.19
Price to Book (P/B)-6.39
Price to Sales (P/S)18.46
P/FCF Ratio-1.76
Enterprise Value/Market Cap1.10
Enterprise Value/Revenue175.65
Enterprise Value/Gross Profit-70.87
Enterprise Value/Ebitda-3.29
Forecast
1Y Price Target
$15.50Price Target Upside95.46% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical ProgressVerastem's VS-7375 has shown promising efficacy in NSCLC patients with a notable 68.8% overall response rate and 93.8% disease control rate, indicating strong clinical activity.
Financial PerformanceVerastem generated $11.2M in net product revenue in its first full quarter post-launch, exceeding BTIG and Street expectations and validating early adoption of AVMAPKI FAKZYNJA Co-Pack.
Market PotentialAvmapki Fakzynja received accelerated approval from the FDA for the treatment of low-grade serous ovarian cancer.
Bears Say
Clinical Study UncertaintyThe need to add 29 additional patients to the confirmatory P3 RAMP 301 study for AF has created some uncertainty.
Efficacy ConcernsThe objective response rate for VS-7375 has decreased from 52% to 41% compared to previous results, which may indicate a decline in efficacy over time.
Stock Market ReactionVSTM stock saw a surprising 20% drop on November 4 despite the strong topline revenues and continued progress on the clinical front.
Verastem News
VSTM FAQ
What was Verastem’s price range in the past 12 months?
Verastem lowest stock price was $3.46 and its highest was $11.24 in the past 12 months.
What is Verastem’s market cap?
Verastem’s market cap is $544.89M.
When is Verastem’s upcoming earnings report date?
Verastem’s upcoming earnings report date is Mar 12, 2026 which is in 124 days.
How were Verastem’s earnings last quarter?
Verastem released its earnings results on Nov 04, 2025. The company reported -$1.35 earnings per share for the quarter, missing the consensus estimate of -$0.617 by -$0.733.
Is Verastem overvalued?
According to Wall Street analysts Verastem’s price is currently Undervalued.
Does Verastem pay dividends?
Verastem does not currently pay dividends.
What is Verastem’s EPS estimate?
Verastem’s EPS estimate is -0.55.
How many shares outstanding does Verastem have?
Verastem has 66,776,010 shares outstanding.
What happened to Verastem’s price movement after its last earnings report?
Verastem reported an EPS of -$1.35 in its last earnings report, missing expectations of -$0.617. Following the earnings report the stock price went down -20.101%.
Which hedge fund is a major shareholder of Verastem?
Currently, no hedge funds are holding shares in VSTM
Verastem Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$15.50 (95.46% Upside)
$15.50 (95.46% Upside)
Blogger Sentiment
Bullish
VSTM Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 62.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $25.5K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▼ 0.4%
Last 30 Days ▲ 1.6%
Last 30 Days ▲ 1.6%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
104.90%
12-Months-Change
Fundamentals
Return on Equity
-2888.70%
Trailing 12-Months
Asset Growth
39.94%
Trailing 12-Months
Company Description
Verastem
Verastem, Inc. (VSTM) is a biopharmaceutical company focused on developing and commercializing medicines to improve the survival and quality of life for cancer patients. The company primarily operates in the oncology sector, with a strong emphasis on targeting malignant cells and the tumor microenvironment. Its core products and services revolve around innovative therapies for cancer treatment, particularly targeting specific pathways involved in cancer cell proliferation and survival.
VSTM Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted successful product launch and strong financial positioning, with significant revenue generation and advancements in clinical trials. However, continued expenses and the need for additional trial enrollment present challenges.View all VSTM earnings summariesVSTM Stock 12 Month Forecast
Average Price Target
$15.50
▲(95.46% Upside)
Technical Analysis
Cardiff Oncology
―
Mereo Biopharma Group Plc
―
Monopar Therapeutics Inc
―
Silence Therapeutics
―
Atea Pharmaceuticals
―
Ownership Overview
1.39% Insiders
7.80% Mutual Funds
48.85% Other Institutional Investors
31.29% Public Companies and
Individual Investors